Brackbill Marcia L, Kidd Robert S, Abdoo April D, Warner James G, Harralson Arthur F
Department of Pharmacy Practice, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA 22601-9975, USA.
Heart Vessels. 2009 Mar;24(2):73-8. doi: 10.1007/s00380-008-1085-2. Epub 2009 Apr 1.
The presence of cytochrome P450 (CYP) variant alleles may reduce the activation of the prodrug clopidogrel to its active state. This research evaluated the frequency of variant alleles in the genes coding for CYP3A4, CYP3A5, CYP2C9, and CYP2C19 enzymes in patients on clopidogrel therapy and experiencing repeat acute coronary syndrome (ACS) compared to a control group with a matching ethnic composition. Real-time polymerase chain reaction was used for allelic discrimination. Complete data were obtained for 92 patients enrolled over a 3-month period. There were no significant differences in the presence of the examined CYP3A4, CYP3A5, CYP2C9, or CYP2C19 variant alleles between the two groups. The present data indicate that patients currently receiving clopidogrel therapy who present with repeat ACS do not have higher frequency of the examined variant alleles compared to a control group.
细胞色素P450（CYP）变异等位基因的存在可能会减少前体药物氯吡格雷向其活性状态的转化。本研究评估了接受氯吡格雷治疗且经历复发性急性冠状动脉综合征（ACS）的患者与种族构成匹配的对照组相比，编码CYP3A4、CYP3A5、CYP2C9和CYP2C19酶的基因中变异等位基因的频率。采用实时聚合酶链反应进行等位基因鉴别。在3个月期间纳入的92例患者获得了完整数据。两组之间检测的CYP3A4、CYP3A5、CYP2C9或CYP2C19变异等位基因的存在无显著差异。目前的数据表明，与对照组相比，目前接受氯吡格雷治疗且出现复发性ACS的患者所检测的变异等位基因频率并不更高。
